Nasus Pharma's NS002 Outperformed EpiPen® in Phase 2. Has the Market Caught Up?

This is sponsored content.  Barchart is not endorsing the websites or products set forth below.

Nasus Pharma recently delivered some of the most compelling pharmacokinetic data in the anaphylaxis space in years, but the company's market cap suggests investors may still be doing the math.

When a drug candidate beats the market standard by roughly 2x on a critical safety metric, statistically significant across multiple timepoints, investors tend to take notice. For Nasus Pharma Ltd. (NYSE: NSRX), the data is there. Whether the market has fully absorbed what it means is a different question.

On March 16, 2026, Nasus released top-line results from its Phase 2 clinical study of NS002, an investigational intranasal epinephrine powder formulation designed as a needle-free alternative to the EpiPen® for patients experiencing anaphylaxis. Nine days later, the company followed with its annual results and a broader business update that added context around funding, pipeline expansion, and the path to a pivotal study. Taken together, the two announcements paint a picture of a company with a validated lead asset, a clear near-term runway, and, if the data holds, a credible shot at disrupting one of the best-recognized drug delivery franchises in consumer healthcare.

The Data: What NS002 Actually Showed

The Phase 2 study enrolled 50 healthy adults with a history of allergic rhinitis. Participants received both NS002 and intramuscular EpiPen® under multiple conditions, including a nasal allergic challenge designed to simulate the kind of environment a patient might actually face during an anaphylactic episode, congested nasal passages and all. That design choice matters. It's one thing to show efficacy in ideal conditions; it's another to show it under physiological stress.

The headline number is the time to therapeutic threshold, defined as reaching 100 pg/mL plasma epinephrine (T100), the concentration generally associated with meaningful clinical effect. NS002 hit that threshold with a median time of 1.69 minutes. EpiPen® took 3.42 minutes. That difference was statistically significant (p=0.033), and it compounds at every timepoint measured:

• At 2.5 minutes: 67.4% of NS002 subjects reached the threshold versus 27.1% with EpiPen® (p=0.0001)
• At 5 minutes: 88.4% versus 64.6% (p=0.0081)
• By 10 minutes: approximately 95% of NS002 subjects had reached the threshold

The drug also reached peak concentration (Tmax) faster, with a median of 15 minutes versus 19.8 minutes for EpiPen®, and total epinephrine absorption in the critical first 10-minute window was approximately 50% higher with NS002. No serious adverse events were reported, and the safety profile was described as consistent with prior studies.

For context: in anaphylaxis, time is not just a clinical metric. It is the ballgame. Anaphylaxis can progress from mild symptoms to cardiovascular collapse in minutes. A treatment that reaches therapeutic levels in under two minutes, reliably under real-world conditions, is addressing the core clinical concern that has driven epinephrine autoinjector development for decades.

So Why Does Any of This Matter for Investors?

The EpiPen® market has long been dominated by a single device with well-documented limitations. It requires injection, demands correct technique under stress, has been the subject of persistent shortages and affordability controversies, and carries the physical and psychological barriers that come with needles. The unmet need for a needle-free alternative with at least comparable (ideally superior) pharmacokinetics has been recognized for years. NS002 appears to have cleared that bar, at least at Phase 2.

That matters because the anaphylaxis treatment market is substantial. Millions of patients in the U.S. alone carry epinephrine autoinjectors, or should be. Allergic disease prevalence has been rising steadily, and awareness campaigns around anaphylaxis preparedness have expanded the prescribing base. A differentiated entrant that can demonstrate superiority in time-to-threshold data, present a cleaner user experience, and survive regulatory scrutiny would enter a market with established demand and known reimbursement pathways.

Nasus isn't claiming the market yet. It's a clinical-stage company, and regulatory approval is still several steps away. But the Phase 2 data gives the company something concrete to carry into its planned pivotal study.

The Road Ahead: Key Catalysts to Watch

Following the Phase 2 results, Nasus confirmed it is advancing NS002 toward a pivotal clinical study expected to initiate in Q4 2026, with a planned readout in Q1 2027, subject to regulatory alignment. The company indicated that the positive Phase 2 results support continued development toward a potential NDA submission.

That timeline is meaningful for a few reasons. First, it's near-term; investors won't be waiting years for a signal. Second, the company has the cash to get there. As of December 31, 2025, Nasus held $4.3 million in cash, cash equivalents, and marketable securities. A $15 million private placement that closed in February 2026 extended the runway materially, and the company stated it expects to be funded through the pivotal study and potential NDA filing, specifically noting cash sufficiency through the second quarter of 2027.

Beyond NS002, Nasus is advancing three additional programs leveraging its proprietary intranasal powder platform: NS003 (ondansetron for chemotherapy-induced nausea and vomiting), NS004 (targeting metabolic disorders), and NS005 (targeting cardiovascular disease). First-in-human Phase 1 studies for NS003 and NS004 are expected to initiate in the second half of 2026. These programs are early-stage and carry the risks inherent to preclinical-to-clinical transitions, but they represent optionality: each one is a potential future asset built on the same delivery platform that NS002 has now validated in a clinical setting.

Annual Results: What the Financials Say

For the year ended December 31, 2025, Nasus reported a net loss of $5.9 million, compared to $1.5 million the prior year. R&D expenses were $2.4 million, up from $0.3 million in 2024, reflecting the ramp-up of NS002 development activity. G&A expenses were $2.7 million, with the increase primarily attributable to the company's transition to public company status following its IPO.

These are the financials of a company spending on its science, not padding overhead. The burn is proportionate to where NS002 is in development, and the February 2026 financing ensures the company isn't going back to the well before the next major data readout.

The Bigger Picture

Small-cap biotech is a space where the market frequently prices in doubt before it prices in data. A company like Nasus (NSRX), recently public with a small share count of approximately 9 million shares outstanding as of year-end 2025 and a limited institutional following, is exactly the kind of name that can deliver genuinely strong results and still trade well below what the clinical story might otherwise support.

The Phase 2 data for NS002 is not equivocal. The statistical significance is real, the clinical rationale is sound, and the design of the study, including the nasal allergic challenge component, was built to anticipate the scrutiny that comes with a pivotal study and eventual regulatory review. That doesn't guarantee success in future trials, and investors should weigh the inherent risks of clinical development accordingly. But when strong data is met with a muted or disconnected market response, it's worth asking whether the skepticism is warranted or whether it reflects the structural tendency of micro-cap biotech stocks to be underappreciated until they aren't.

With a pivotal study on the calendar for Q4 2026 and a readout just months away from that, Nasus Pharma will have an opportunity to either confirm or complicate the story the Phase 2 data has started to tell. For investors who follow the science closely, the setup appears to be worth watching.

The above is sponsored content. Barchart was paid up to eleven thousand dollars for placement and promotion of the content on this site and other forms of public distribution covering the period of September 2025 - April 2026.  For more information please view the Barchart Disclosure Policy here.